iDayo Selects NOVT as Low Risk Investment

Call Now
800-993-0005

(^DJI) 0

0S&P 500 (^GSPC) 1320.68

1.82NASDAQ Composite (^IXIC) 2839.38

-10.74Russell 2000 (^RUT) 766.57

1.4

iDayo™ Stock Selector: NOVT - Novt Corp Common Share

iDayo™ 06/16/03: Novt Corp Common Share (NOVT) - 06/16/03

For the 16 week investment period starting 06/16/03 , the iDayo™ Stock Selector rated Novt Corp Common Share (NOVT) as "Significant Accumulation" and selected NOVT as a buy for the investment period, identified as iDayo™ 06/16/03.

Company Profile for "Novt Corp Common Share (NOVT)": Novoste Corporation has developed the Beta-Cath System, a handheld device to deliver beta (low penetration) radiation to the site of a treated blockage in a coronary artery to decrease restenosis, the renarrowing of a previously treated artery.

Google Finance History for NOVT

iDayo, Inc. (including its marketing professionals and staff), is not a registered Investment Advisor or Broker/Dealer, and does not provide investment advice or recommendations. Subscribers to iDayo™ are advised that the information, opinions, and analysis included in our web sites, on our free Educational Conference Calls, or in any other communication are based in good faith on sources believed to be reliable, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness, or correctness.

Past performance is not necessarily indicative of the future performance of stocks posted. None of these postings, the iDayo™ system rating, nor any other information provided on our web sites, on our free Educational Conference Calls, or in any other communication constitutes a recommendation to buy or sell stocks or any other investment. Investing involves the risk of loss and Subscribers are urged to consult with their own independent financial advisors with respect to any investment.